Cellectis
CLLS
28 hedge funds and large institutions have $23.7M invested in Cellectis in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
23,700% more call options, than puts
Call options by funds: $238K | Put options by funds: $1K
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more funds holding
Funds holding: 24 → 28 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
3.44% less ownership
Funds ownership: 11.72% → 8.28% (-3.4%)
85% less capital inflows, than outflows
Capital inflows: $955K | Capital outflows: $6.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$575K |
| 2 |
Virtu Financial
New York
|
+$65.3K |
| 3 |
BGI
B Group Inc
Dallas,
Texas
|
+$64.8K |
| 4 |
DRD
Dennis R. Delaney
|
+$62.2K |
| 5 |
Millennium Management
New York
|
+$57.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$4.85M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$1.54M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$36.3K |
| 4 |
First Affirmative Financial Network
Colorado Springs,
Colorado
|
-$25K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$17K |
CLLS Hedge Fund Activity: Q3 2025 in Review
28 of the 7,650 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q3 2025, worth a combined $23.7M — up 33% from $17.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CLLS positions and 3 closed out — a net gain of 4 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $575K. The largest seller was UBS AM, exiting entirely with an estimated $4.85M sold.
- 28 institutional investors held Cellectis (CLLS) as of Q3 2025, up from 24 in Q2 2025.
- Funds reported $23.7M of Cellectis stock for Q3 2025, up 33% quarter-over-quarter.
- 7 funds opened new Cellectis positions in Q3 2025 and 3 closed out, a net change of +4 holders.
- The largest Cellectis buyer in Q3 2025 was Citadel Advisors, an estimated $575K added.
- The largest Cellectis seller in Q3 2025 was UBS AM, an estimated $4.85M sold.
Based on aggregated 13F filings for Q3 2025.